Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...
Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...
Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment
Veru anticipates filing a new IND for sabizabulin to address inflammation in atherosclerotic cardiovascular disease, with Phase 2 studies using coronary CT angiography as the primary endpoint. IND ...
Veru Inc (VERU) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor ...
Earnings call transcript: Veru Inc Q1 2025 beats EPS forecast, stock dips
Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million, surpassing the forecast of ...
Veru reports Q1 cont-op EPS (1c) vs. (8c) last year
Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
manilatimes20h
Ducommun Incorporated Announces Fourth Quarter Conference Call
Ducommun Incorporated (NYSE: DCO) ("Ducommun” or the "Company”) today announced that it plans to release the Company's 2024 fourth quarter financial results on February 27, 2025, prior to the stock ...